Compare DexCom, Inc. (DXCM) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs MPLX LP — how do they compare? DexCom, Inc. trades at $78.45 (market cap $28.06B), while MPLX LP trades at $56.74 (market cap $57.24B). The key difference: MPLX LP is far larger — about 2× DexCom, Inc.'s market cap, and MPLX LP pays a 7.63% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | MPLX | |
|---|---|---|
Market Cap | $28.06B | $57.24B |
Sector | Health | Technology |
52-Week High | $89.53 | $59.17 |
52-Week Low | $54.84 | $47.80 |
Enterprise Value | $27.03B | $81.87B |
Dividend Yield | — | 7.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
MPLX trades at $56.50, showing minimal daily movement with a slight 0.02% decline. The stock maintains strong profitability with 41.24% net income margin and 33.67% ROE, though technical indicators signal bearish momentum. Recent earnings showed mixed results with Q1 2026 missing expectations after two consecutive beats. Analyst consensus remains strongly positive with 71% buy ratings and a $60.60 price target, representing 7.3% upside potential from current levels.
MPLX offers attractive income potential with sustainable dividends and robust cash flow generation, though investors face headwinds from bearish technical signals and potential earnings volatility. The company's fee-based midstream model provides stability against commodity price swings, but execution risks and market sentiment shifts warrant careful monitoring for equity investors seeking energy infrastructure exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
